GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31

GeoVax Labs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026

$0.23−0.01 (-4.53%)

Close on Oct 19, 2026

Market cap: $1.04M
P/E (TTM): –
Dividend yield: –

Community

Notes and questions about GeoVax Labs from other investors

No posts about GOVX yet

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in GeoVax Labs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jan 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GOVX.

Revenue growth-100.0% · median 52.0%

Company	Revenue	Growth
NWBO	$2.17M	+98.6%
VCNX	$601.00K	+5.4%
GOVX	$0	-100.0%
PVCT	–	–
ANIX	–	–
TRAW	–	–

Company

Next earnings (est.): Nov 12, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 6.7%
Auditor: WIPFLI LLP
SEC CIK: 832489

Advertisement
300 × 250